Results 241 to 250 of about 254,836 (309)

Aerobic Exercise Preconditioning Does Not Augment Muscle Hypertrophy During Subsequent Resistance Exercise Training in Healthy Older Adults. [PDF]

open access: yesSports Med
Betz MW   +10 more
europepmc   +1 more source

A Comprehensive Review of the Genetic Etiology and Management of Orofacial Clefts

open access: yesPediatric Discovery, EarlyView.
ABSTRACT Cleft lip (CL) and cleft palate (CP), collectively referred to as orofacial clefts (OFCs), are among the most common birth defects and can have significant effects on speech, nutrition, and physical and psychosocial development. Manifestation, classification, and treatment plans of OFCs are diverse and not standardized.
Emily Kim   +3 more
wiley   +1 more source

Amentoflavone, a Preferentially TGF‐β Receptor 1 Inhibitor, Alleviates Cardiac Remodeling and Dysfunction Through Modulating the TGF‐β/Smad and MAPK Signaling Pathways

open access: yesPhytotherapy Research, EarlyView.
Amentoflavone, a preferentially TGF‐ββ receptor 1 inhibitor, attenuates transverse aortic constriction (TAC)‐triggered cardiac hypertrophy, fibrosis, and dysfunction by suppressing downstream Smad and MAPK signaling cascades in cardiomyocytes and cardiac fibroblasts.
Jiangjiao Wu   +10 more
wiley   +1 more source

6‐Shogaol Attenuates Doxorubicin‐Induced Cardiac and Skeletal Muscle Atrophy by Inhibiting E3 Ubiquitin Ligases and Necroptosis

open access: yesPhytotherapy Research, EarlyView.
Doxorubicin induces cardiac and skeletal muscle atrophy by upregulating E3 ubiquitin ligases, inhibiting myogenic regulatory factors, and activating necroptosis. Cardiac atrophy can further exacerbate cardiotoxicity. 6‐Shogaol negatively regulates these processes and attenuates doxorubicin‐induced cardiac and skeletal muscle atrophy.
Xipeng Sun   +5 more
wiley   +1 more source

Hederagenin Attenuates Cardiac Remodeling by Targeting Phosphodiesterase 9A

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT Background and Aim New therapeutic strategies for heart failure are urgently needed. The protective effects of cyclic guanosine monophosphate (cGMP)—protein kinase G (PKG) pathway on heart have been widely reported. Despite phosphodiesterase 9A (PDE9A) inhibitors combating cardiac remodeling, clinically available drugs are lacking. Hederagenin
Liqian Chen   +16 more
wiley   +1 more source

Resistance Training in a Patient With Hypokalemic Periodic Paralysis and Permanent Weakness: A Case Report

open access: yes
Muscle &Nerve, EarlyView.
Jeppe Moesgaard Rasmussen   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy